分类学特征、抗病毒活性及 Nocardiopsis sp. CG3 中三种新 Kenalactams 的诱导

Taxonomic Characterization, Antiviral Activity and Induction of Three New Kenalactams in Nocardiopsis sp. CG3.

机构信息

Microbiology Laboratory Applied to Food Biomedical and Environmental (LAMAABE), Faculty of SNV-STU-Ex Imama Biomedical Complex, University of Abou Bekr Belkaid, PB 119, 13000, Tlemcen, Algeria.

Helmholtz Centre for Infection Research (HZI), Microbial Strain Collection, 38124, Brunswick, Germany.

出版信息

Curr Microbiol. 2022 Aug 10;79(9):284. doi: 10.1007/s00284-022-02954-x.

DOI:10.1007/s00284-022-02954-x

PMID:35947206

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9363871/

Abstract

Exploration of secondary metabolites secreted by new Actinobacteria taxa isolated from unexplored areas, can increase the possibility to obtain new compounds which can be developed into new drugs for the treatment of serious diseases such as hepatitis C. In this context, one actinobacterial strain, CG3, has been selected based on the results of polyphasic characterization, which indicate that it represents a new putative species within the genus Nocardiopsis. Two fractions (F2 and F3), prepared from the culture of strain CG3 in soybean medium, exhibited a pronounced antiviral activity against the HCV strain Luc-Jc1. LC-HRESIMS analysis showed different bioactive compounds in both active fractions (F2 and F3), including five polyenic macrolactams (kenalactams A-E), three isoflavone metabolites, along with mitomycin C and one p-phenyl derivative. Furthermore, feeding with 1% of methionine, lysine or alanine as a unique nitrogen source, induced the production of three novel kenalactam derivatives.

摘要

从未开发区域分离出的新型放线菌分类群分泌的次生代谢产物的探索，增加了获得新化合物的可能性，这些化合物可以开发成治疗丙型肝炎等严重疾病的新药。在这种情况下，根据多相特征分析的结果，选择了一株放线菌 CG3，该菌代表了诺卡氏菌属中的一个新的假定种。从 CG3 菌株在大豆培养基中的培养物中制备的两个馏分（F2 和 F3）对 HCV 株 Luc-Jc1 表现出明显的抗病毒活性。LC-HRESIMS 分析表明，两个活性馏分（F2 和 F3）中含有不同的生物活性化合物，包括五种聚烯大环内酯（肯纳内酯 A-E）、三种异黄酮代谢物，以及丝裂霉素 C 和一个对苯衍生物。此外，以 1%的蛋氨酸、赖氨酸或丙氨酸作为唯一的氮源进行喂养，诱导产生了三种新型肯纳内酯衍生物。